2023 ICD-10-CM Diagnosis Code C94.8

Other specified leukemias

    2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
  • C94.8 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2023 edition of ICD-10-CM C94.8 became effective on October 1, 2022.
  • This is the American ICD-10-CM version of C94.8 - other international versions of ICD-10 C94.8 may differ.
Applicable To
  • Aggressive NK-cell leukemia
  • Acute basophilic leukemia
The following code(s) above C94.8 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C94.8:
  • C00-D49
    2023 ICD-10-CM Range C00-D49


    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
  • C81-C96
    2023 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C94
    ICD-10-CM Diagnosis Code C94

    Other leukemias of specified cell type

      2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • leukemic reticuloendotheliosis (C91.4-)
    • myelodysplastic syndromes (D46.-)
    • personal history of leukemia (Z85.6)
    • plasma cell leukemia (C90.1-)
    Other leukemias of specified cell type
Clinical Information
  • A rare acute myeloid leukemia in which the primary differentiation is to basophils. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.
  • A rare, highly aggressive, epstein-barr virus-associated leukemia, also known as aggressive nk-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal nk/t-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of nk cells in the peripheral blood, bone marrow, liver, and spleen.
  • An acute myeloid leukemia in which the immature cells differentiate towards basophils. This is a rare leukemia. The observed cases have been associated with a poor prognosis. The term basophilic leukemia is used as a synonym for acute basophilic leukemia. Chronic basophilic leukemia is an inappropriate term vaguely connected to the term mast cell leukemia. (who, 2001)
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change

Diagnosis Index entries containing back-references to C94.8:

ICD-10-CM Codes Adjacent To C94.8
C94.22 …… in relapse
C94.3 Mast cell leukemia
C94.30 …… not having achieved remission
C94.31 …… in remission
C94.32 …… in relapse
C94.4 Acute panmyelosis with myelofibrosis
C94.40 …… not having achieved remission
C94.41 …… in remission
C94.42 …… in relapse
C94.6 Myelodysplastic disease, not elsewhere classified
C94.8 Other specified leukemias
C94.80 …… not having achieved remission
C94.81 …… in remission
C94.82 …… in relapse
C95 Leukemia of unspecified cell type
C95.0 Acute leukemia of unspecified cell type
C95.00 …… not having achieved remission
C95.01 …… in remission
C95.02 …… in relapse
C95.1 Chronic leukemia of unspecified cell type
C95.10 …… not having achieved remission

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.